The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis
Open accessAbstract
Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in overweight/obese patients without diabetes. The random-effect model was used to pool data extracted from included literatures. The weighted mean difference (WMD), odds ratio and 95% confidence interval (CI) were used to present the meta-analysis results (PROSPERO registration number: CRD 42020173199). The sources of intertrial heterogeneity, bias and the robustness of results were evaluated by subgroup analysis, sensitivity analysis and regression analysis, respectively. A total of 24 RCTs were recruited in the present analysis which included 5867 patients. The results showed that the treatment of overweight/obese patients without diabetes with GLP-1RAs including liraglutide, exenatide and semaglutide significantly achieved greater weight loss than placebo [WMD=–5.39, 95% CI (–6.82, –3.96)] and metformin [WMD=–5.46, 95% CI (–5.87, –5.05)]. The subgroup analysis showed that semaglutide displayed the most obvious antiobesity effect in terms of weight loss, the reduction of body mass index (BMI) and waist circumference (WC). However, GLP-1RAs treatments had more gastrointestinal adverse events (such as nausea and vomiting) than placebo and Met. The subgroup analysis also represented that semaglutide displayed the lowest risk of gastrointestinal adverse events among three kinds of GLP-1RAs. Our meta-analysis demonstrated that GLP-1RA had a superior antiobesity effect than placebo/Met in overweight/obese patients without diabetes in terms of body weight, BMI, and WC, especially for semaglutide, which had more obvious antiobesity effect and lower GI adverse events than liraglutide and exenatide.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Systematic reviews and meta-analyses of GLP-1 receptor agonists reported that subcutaneous semaglutide reduced weight and improved weight-related comorbidities significantly more than liraglutide and was associated with lower rates of gastrointestinal adverse events.
“Systematic reviews and meta-analyses of GLP-1 receptor agonists reported that subcutaneous semaglutide reduced weight and improved weight-related comorbidities significantly more than liraglutide and was associated with lower rates of gastrointestinal adverse events.101,102”
From Obesity Management in Adults (2023) · cites this paper as [102]
Cites
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · see citing works
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · see citing works
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444 · see citing works
Benefits and Risks of Bariatric Surgery in Adults: A Review
Arterburn, D. E., Telem, D. A., Kushner, R. F., & Courcoulas, A. P. (2020) · JAMA · doi:10.1001/jama.2020.12567 · Cited by 1,251 · see citing works
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · see citing works
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114 · see citing works
O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814 · see citing works
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693 · see citing works
Wadden, T., Hollander, P., Klein, S., Niswender, K., Woo, V., Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2014.88 · Cited by 627 · see citing works
Bethel, M. A., Patel, R. A., Merrill, P., Lokhnygina, Y., Buse, J. B., Mentz, R. J., Pagidipati, N. J., Chan, J. C., Gustavson, S. M., Iqbal, N., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30412-6 · Cited by 599 · see citing works
on behalf of the SCALE study group, Blackman, A., Foster, G. D., Zammit, G., Rosenberg, R., Aronne, L., Wadden, T., Claudius, B., Jensen, C. B., & Mignot, E. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.52 · Cited by 583 · see citing works
Htike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12849 · Cited by 418 · see citing works
Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · see citing works
Maggio, C. A., & Pi-Sunyer, X. (2003) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(03)00071-9 · Cited by 352 · see citing works
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821997320 · Cited by 289 · see citing works
Elkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0115 · Cited by 276 · see citing works
Rosenstock, J., Klaff, L. J., Schwartz, S., Northrup, J., Holcombe, J. H., Wilhelm, K., & Trautmann, M. (2010) · Diabetes Care · doi:10.2337/dc09-1203 · Cited by 229 · see citing works
Frøssing, S., Nylander, M., Chabanova, E., Frystyk, J., Holst, J. J., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13053 · Cited by 178 · see citing works
Jensterle Sever, M., Kocjan, T., Pfeifer, M., Kravos, N. A., & Janez, A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0797 · Cited by 175 · see citing works
Semaglutide as a promising antiobesity drug
Christou, G. A., Katsiki, N., Blundell, J., Fruhbeck, G., & Kiortsis, D. N. (2019) · Obesity Reviews · doi:10.1111/obr.12839 · Cited by 159 · see citing works
Dushay, J. R., Gao, C., Gopalakrishnan, G. S., Crawley, M. B., Mitten, E. K., Wilker, E. H., Mullington, J. M., & Maratos–Flier, E. (2011) · Diabetes Care · doi:10.2337/dc11-0931 · Cited by 149 · see citing works
Liu, X., Zhang, Y., Zheng, S., Lin, R., Xie, Y., Chen, H., Zheng, Y., Liu, E., Chen, L., Yan, J., et al. (2017) · Clinical Endocrinology · doi:10.1111/cen.13454 · Cited by 149 · see citing works
Lund, A., Knop, F. K., & Vilsbøll, T. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.03.005 · Cited by 148 · see citing works
Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes
Kim, S. H., Abbasi, F., Lamendola, C. A., Liu, A., Ariel, D., Schaaf, P., Grove, K., Tomasso, V., Ochoa, H., Liu, Y. V., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0354 · Cited by 118 · see citing works
Jensterle, M., Kravos, N. A., Pfeifer, M., Kocjan, T., & Janez, A. (2015) · Hormones · doi:10.1007/bf03401383 · Cited by 117 · see citing works
Robert, S. A., Ghani, R. A., Shah, S. A., Chinna, K., Mohamud, W. N. W., & Kamaruddin, N. A. (2015) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2015.03.005 · Cited by 104 · see citing works
Jensterle, M., Salamun, V., Kocjan, T., Vrtacnik Bokal, E., & Janez, A. (2015) · Journal of Ovarian Research · doi:10.1186/s13048-015-0161-3 · Cited by 103 · see citing works
A Role for GLP-1 in Treating Hyperphagia and Obesity
Grill, H. J. (2020) · Endocrinology · doi:10.1210/endocr/bqaa093 · Cited by 101 · see citing works
Kelly, A. S., Bergenstal, R. M., Gonzalez-Campoy, J., Katz, H., & Bank, A. J. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-64 · Cited by 98 · see citing works
Faurschou, A., Gyldenløve, M., Rohde, U., Thyssen, J. P., Zachariae, C. O. C., Skov, L., Knop, F. K., & Vilsbøll, T. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12629 · Cited by 90 · see citing works
Roth, C. L., Perez, F. A., Whitlock, K. B., Elfers, C., Yanovski, J. A., Shoemaker, A. H., & Abuzzahab, M. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14224 · Cited by 87 · see citing works
Weghuber, D., Forslund, A. H., Ahlström, H. K., Alderborn, A., Bergström, K., Brunner, S. M., Cadamuro, J., Ciba, I., Dahlbom, M., Heu, V., et al. (2020) · Pediatric Obesity · doi:10.1111/ijpo.12624 · Cited by 79 · see citing works
Zhang, F., Tong, Y., Su, N., Li, Y., Tang, L., Huang, L., & Tong, N. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12198 · Cited by 59 · see citing works
Li, J., He, K., Ge, J., Li, C., & Jing, Z. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108656 · Cited by 41 · see citing works
Zheng, S., Zhang, Y., Long, T., Lu, J., Liu, X., Yan, J., Chen, L., Gong, Y., & Wang, F. (2017) · Obesity Medicine · doi:10.1016/j.obmed.2017.06.003 · Cited by 39 · see citing works
Su, N., Li, Y., Xu, T., Li, L., Kwong, J. S.-W., Du, H., Ren, K., Li, Q., Li, J., Sun, X., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.028 · Cited by 30 · see citing works
Liraglutide is an effective drug for the treatment of obesity also in real life
Piantanida, E., Gallo, D., & Tanda, M. L. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01348-9 · Cited by 4 · see citing works
Flagged first, then by citations
1 of the 38 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Elmaleh-Sachs, A., Schwartz, J. L., Bramante, C. T., Nicklas, J. M., Gudzune, K. A., & Jay, M. (2023) · JAMA · doi:10.1001/jama.2023.19897 · Cited by 748 · see citing works
Elsaid, M. I., Li, N., Firkins, S. A., Rustgi, V. K., Paskett, E. D., Acharya, C., Reddy, K. R., Chiang, C. W., & Mumtaz, K. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17925 · Cited by 77 · see citing works
Idiopathic intracranial hypertension: a step change in understanding the disease mechanisms
Yiangou, A., Mollan, S. P., & Sinclair, A. J. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00893-0 · Cited by 72 · see citing works
Zhou, L., Qu, H., Yang, L., & Shou, L. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01500-5 · Cited by 66 · see citing works
Aoun, L., Almardini, S., Saliba, F., Haddadin, F., Mourad, O., Jdaidani, J., Morcos, Z., Saidi, I. A., Sanayeh, E. B., Saliba, S., et al. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100333 · Cited by 69 · see citing works
Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence
Herman, R. J., & Schmidt, H. D. (2024) · Physiology & Behavior · doi:10.1016/j.physbeh.2024.114565 · Cited by 53 · see citing works
Bak, M., Campforts, B. C. M., Domen, P. A. E., van Amelsvoort, T., & Drukker, M. (2024) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13734 · Cited by 52 · see citing works
Almeida, G. D. O., Nienkotter, T. F., Balieiro, C. C. A., Pasqualotto, E., Cintra, J. B., Carvalho, H. C. P., Silva, A. L. S., Kabariti, J. C., Minucci, B. S., Bertoli, E. D., et al. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00647-3 · Cited by 46 · see citing works
Petek, T. H., & Varda, N. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179706 · Cited by 35 · see citing works
Patoulias, D., Michailidis, T., Dimosiari, A., Fragakis, N., Tse, G., & Rizzo, M. (2023) · Biomedicines · doi:10.3390/biomedicines11030669 · Cited by 27 · see citing works
The interplay between leptin, glucocorticoids, and GLP1 regulates food intake and feeding behaviour
Perez‐Leighton, C. E., Kerr, B., Scherer, P. E., Baudrand, R. F., & Cortés, V. (2023) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.13039 · Cited by 22 · see citing works
Breit, S., & Hubl, D. (2025) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2025.107415 · Cited by 20 · see citing works
Antidiabetic Drugs in Breast Cancer Patients
Garczorz, W., Kosowska, A., & Francuz, T. (2024) · Cancers · doi:10.3390/cancers16020299 · Cited by 21 · see citing works
Glucagon-like Peptide-1 Agonists
Chan, P. Y. W., Mika, A. P., Martin, J. R., & Wilson, J. M. (2024) · JBJS Reviews · doi:10.2106/jbjs.rvw.23.00167 · Cited by 19 · see citing works
Steven, S., Kuntić, M., Münzel, T. F., & Daiber, A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100082 · Cited by 20 · see citing works
Novel Treatments for Obesity: Implications for Cancer Prevention and Treatment
Cuttica, C. M., Briata, I. M., & DeCensi, A. (2023) · Nutrients · doi:10.3390/nu15173737 · Cited by 18 · see citing works
Wang, Y., Wang, J., Gong, Q., Wu, H., Yang, S., He, J., Hu, X., & Huang, T. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej23-0384 · Cited by 18 · see citing works
Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases
Himmerich, H., Bentley, J., & McElroy, S. L. (2024) · CNS Drugs · doi:10.1007/s40263-024-01111-1 · Cited by 18 · see citing works
GLP-1 Receptor Agonists in Orthopaedic Surgery: Implications for Perioperative Care and Outcomes
Ramanathan, R., Lee, J. Y., Dalton, J., Lin, R. T., Lee, I., Gonzalez, C., Shaw, J. D., Schroeder, G. D., Kepler, C. K., Spitnale, M. J., et al. (2025) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.24.01287 · Cited by 16 · see citing works
Ajabnoor, G., Hashim, K. T., Alzahrani, M., Alsuheili, A. Z., Alharbi, A. F., Alhozali, A., Enani, S., Eldakhakhny, B., & Elsamanoudy, A. (2023) · Diseases · doi:10.3390/diseases11010050 · Cited by 17 · see citing works
Campforts, B. C. M., Drukker, M., van Amelsvoort, T., & Bak, M. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06317-7 · Cited by 17 · see citing works
Ghali, A. N., Lawand, J. J., Mitchell, P., Momtaz, D., Ghilzai, U. M., Phan, E. N., Alawa, J., & Deveza, L. R. (2025) · Clinical Spine Surgery A Spine Publication · doi:10.1097/bsd.0000000000001800 · Cited by 13 · see citing works
Katole, N. T., Salankar, H. V., Khade, A. M., Kale, J. S., Bankar, N. J., Gosavi, P. A., Dudhe, B., Mankar, N., & Noman, O. (2024) · Cureus · doi:10.7759/cureus.66280 · Cited by 11 · see citing works
Tummala, S., Gibbs, D. L., Chavarria, J. C., Alder, J., Avramis, I., & Rizkalla, J. (2025) · Journal of Orthopaedics · doi:10.1016/j.jor.2025.05.018 · Cited by 13 · see citing works
Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review
Dias, D. D., Vasconcelos, A. R., Souza, A. C. R., Menezes, C. D., Silva, I. S. T. E., & Name, J. J. (2025) · Obesities · doi:10.3390/obesities5040088 · Cited by 8 · see citing works
Santos, G. L., dos Santos, C. F., Rocha, G. R., Calmon, M. S., Lemos, F. F. B., Silva, L. G., Luz, M. S., Pinheiro, S. L. R., Botelho, A. C., & de Melo, F. F. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i6.104706 · Cited by 9 · see citing works
Nanomedicine as a Promising Treatment Approach for Obesity
Alanazi, A., Craven, A., Spirou, S. V., Santos-Martínez, M. J., Medina, C., & Gobbo, O. L. (2025) · Journal of Nanotheranostics · doi:10.3390/jnt6030021 · Cited by 6 · see citing works
GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis
Alves, K. M., da Silva, M. T., Kramer, C. K., & Viana, L. V. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf150 · Cited by 9 · see citing works
Tanashat, M., Al‐Ajlouni, Y. A., Abuelazm, M., Altobaishat, O., Manasrah, A., Turkmani, M. M., Khan, U., & Abouzid, M. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00726-z · Cited by 6 · see citing works
Gluud, L. L. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.07.007 · Cited by 6 · see citing works
Exenatide for obesity in children and adolescents: Systematic review and meta-analysis
Chen, B., Zou, Z., Zhang, X., Xiao, D., & Li, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1290184 · Cited by 5 · see citing works
Leziak, A., Kochman, K., & Kocełak, P. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.03.008 · Cited by 4 · see citing works
Vahora, I., Moparthi, K. P., Rushaidi, M. T. A., Muddam, M. R., Obajeun, O. A., Abaza, A., Jaramillo, A. P., Idris, F. S., Shaikh, H. A., & Mohammed, L. (2024) · Cureus · doi:10.7759/cureus.65050 · Cited by 4 · see citing works
Fatima, N., Anand, A., Palvia, A. R., Kaur, A., Azeez, G. A., Thirunagari, M., & Butt, S. R. (2024) · Cureus · doi:10.7759/cureus.68786 · Cited by 4 · see citing works
Kamrul-Hasan, A. B. M., Dutta, D., Nagendra, L., Basavarajappa, S. D., Girijashankar, H. B., Joshi, A., & Pappachan, J. M. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i12.112830 · Cited by 3 · see citing works
Hu, X., Wang, Y., Yang, K., & Li, X. (2025) · Endocrine · doi:10.1007/s12020-025-04179-x · Cited by 3 · see citing works
Babiker, A. M. I., Alfaraidi, H., Aljarallah, G. S., Albaraki, J., Alharbi, R., Alsomali, N., Alkhalaf, A., Yenugadhati, N., Juraibah, F. A., & Alwan, I. A. A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1573109 · Cited by 2 · see citing works
Elbashir, R. M. A., Elbashir, A., Basake, R. U., Mohieldin, A. Z. A., Elhaj, N. A. E., Ebrahim, F. E. M., Ahmed, W. G., & Mahgoub, O. A. M. (2025) · Cureus · doi:10.7759/cureus.95938 · Cited by 2 · see citing works
GLP ‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs
Vienghirun, J., Sawangjit, R., Suttiruksa, S., Chaiyakunapruk, N., Jinathongthai, P., Khunti, K., & Lee, S. W. H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70698 · Cited by 2 · see citing works
Almemari, S., Almulla, N., Alsarraf, Y., Badri, G., & Khan, N. S. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02273-3 · Cited by 2 · see citing works
Uso da semaglutida no tratamento da obesidade e sua segurança: uma revisão narrativa
Omizzolo, J. A. E., Schvinn, N. H. F. F., & Batista, L. E. F. T. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n2-154 · Cited by 2 · see citing works
Lu, D., Zheng, R., Li, A., & Zhang, J. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.98552 · Cited by 2 · see citing works
Srour, L., Ismail, J., Njeim, R., & Eid, A. A. (2024) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-3-031-62131-4_8 · Cited by 1 · see citing works
Wong, S., Fabiano, N., Zhou, C., Luu, B., Shorr, R., Slassi, S., Solmi, M., Husain, M. I., & Mak, M. S. B. (2025) · Psychiatry International · doi:10.3390/psychiatryint6030111 · Cited by 1 · see citing works
Cichoń, K., Chyćko, M., CZARNOTA, J., Kromer, A., Zapała, M. A., Środoń, A., Wilk, J., Cholewa, M. M., Gawryś, A., & Łapaj, M. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.35.01.008 · Cited by 1 · see citing works
GLP-1 receptor agonists for weight loss, benefits and risks: A systematic review of the literature
de Moraes, D. S. P., & Estrín, M. A. (2024) · Salud Ciencia y Tecnología - Serie de Conferencias · doi:10.56294/sctconf2024.719 · Cited by 1 · see citing works
Taha, S. T., & Abbas, L. B. (2023) · ZANCO Journal of Pure and Applied Sciences · doi:10.21271/zjpas.35.1.21
Exenatide for obesity in children and adolescents: Systematic Review and Meta-analysis (Preprint)Preprint
Li, X., Chen, B., Xiao, D., Zou, Z., & Zhang, X. (2023) · doi:10.2196/preprints.48486
Arruda, T. B., Júnior, J. A. T. L., de Albuquerque, T. M., Coelho, R. V., Melo, A. A. J., & Bachur, T. P. R. (2023) · Revista Intertox de Toxicologia Risco Ambiental e Sociedade · doi:10.22280/revintervol16ed2.545
Pires, D. F., Fonseca, M. C. M., Cabanelas, L. L., Fonseca, R. C. M., & Lobo, M. J. M. (2024) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2024v6n5p36-48
Which GLP1 receptor agonist approved for weight loss is the most effective at achieving weight loss?
Abresch-Meyer, A., Aulakh, T., Domingo, P., Harris, T., & Tagle, A. (2024) · Evidence-Based Practice · doi:10.1097/ebp.0000000000002179
Glucagon-like peptide-1 receptor agonists and derivatives in the treatment of obesity - review
Rabenda, M., Słomczyński, A., Zatyka, P., Pawłowska, A., Opala, D., Osuch, D., & Janik, P. E. (2024) · Quality in Sport · doi:10.12775/qs.2024.20.53995
Bolivar, K., Carver, T., LeMire, N., & Williams, E. (2024) · Evidence-Based Practice · doi:10.1097/ebp.0000000000002262
Vienghirun, J., Sawangjit, R., Suttiruksa, S., Chaiyakunapruk, N., Jinathongthai, P., Khunti, K. K., & Lee, S. W. H. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5372118
Zhou, L., Qu, H., Yang, L., & Shou, L. (2024) · Figshare · doi:10.6084/m9.figshare.26637207
Peng, T., Liang, W., Wei, J., Ding, N., Tang, X., & Zhang, Z. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s590529
Digital Augmentation of Glucagon-Like Peptide-1 for Obesity Management: Retrospective Study
Davey, B., Dabash, O., Khanna, R., Cornell, P. Y., & Huckvale, K. (2026) · Journal of Medical Internet Research · doi:10.2196/100728
Depression Associated with Other Medical Conditions
Sunzeri, F., & Sunzeri, E. (2026) · Springer eBooks · doi:10.1007/978-3-032-14465-2_12
- Authors
- Guo, X., Zhou, Z., Lyu, X., Xu, H., Zhu, H., Pan, H., Wang, L., Yang, H., & Gong, F.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- ORCID
- Venue
- Hormone and Metabolic Research
- Publisher
- Georg Thieme Verlag KG
- Published
- 2022-05-05
- Volume
- 54
- Issue
- 07
- Pages
- 458-471
- ISSN
- 0018-5043 (ISSN-L)
- 1439-4286
- OpenAlex
- W4229012762
- Cited by
- 59
- References
- 38
- Citations by year
- 2026: 6 · 2025: 16 · 2024: 24 · 2023: 13
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hormone and Metabolic Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- CAMS Innovation Fund for Medical Sciences ((2021-1-I2M-002)
- National Key Program of Clinical Science (WBYZ2011-873)
- Beijing Natural Science Foundation (7222137, 7182130, 7082079)
- PUMCH Foundation (2013-020)
- National Natural Science Foundation of China (81370898, 30771026)
- China Diabetes Young Scientific Talent Research Project (2020-N-01-10)
- Topics
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, obesity, overweight, weight loss, semaglutide, liraglutide, exenatide, metformin, gastrointestinal adverse effects, body mass index, waist circumference, non-diabetic obesity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
